Modeling statin-induced reductions of cardiovascular events in primary prevention: A VOYAGER meta-analysis

Björn W. Karlson, Stephen J. Nicholls, Pia Lundman, Philip J. Barter, Michael K. Palmer

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


Objective: We used individual patient data from the VOYAGER database to estimate cardiovascular (CV) risk reduction with commonly used high-intensity statins. Methods: In patients with known atherosclerotic CV disease (ASCVD) treated with high-intensity statin therapy (n = 6,735), the predicted risk reduction was estimated using the Cholesterol Treatment Trialists' Collaboration meta-analysis, which determined risk reduction per 38.7 mg/dL statin-mediated reduction in low-density lipoprotein cholesterol. Results: The greatest reductions in risk were seen in major vascular events (estimated rate ratios ranged from 0.55 with rosuvastatin [RSV] 40 mg to 0.60 with atorvastatin [ATV] 40 mg) and coronary heart disease death (estimated rate ratios ranged from 0.58 with RSV 40 mg to 0.64 with ATV 40 mg). Conclusions: Our results show that, in individuals without clinical ASCVD, statin therapy has the potential to reduce the frequency of CV events.

Original languageEnglish
Pages (from-to)30-34
Number of pages5
Issue number1
Publication statusPublished - 1 Jun 2018
Externally publishedYes


  • Cardiovascular diseases
  • Lipids
  • Risk factors
  • Statins

Cite this